Scaling Biotech Manufacturing in the Netherlands: Project Structures That Enable Growth
The Netherlands has managed to place itself subtly at the forefront of some of the biggest biotech clusters in Europe. Leiden Bio Science Park, Pivot Park, and Utrecht Science Park are witnessing an unprecedented rate of innovation in the country. The latest treatments are being taken a step further in clinical trials.
The financial front for biotechnology is expanding. Startups are advancing/expanding their operations faster than ever before. However, there is a time when every biotech company has to face this problem.
Firstly, research is a success. Secondly, clinical results are promising. Thirdly, funding is arranged and then comes the major problem.
Manufacturing.
Growing biotech manufacturing under the regulatory environment is an entirely different ball game than conducting a research laboratory. It brings in operational complexity, regulatory oversight and an intense demand for experts with the right skills.
From our perspective working within the Dutch life sciences ecosystem, this transition is where many companies either accelerate… or stall.
Let’s unpack why.
Why Scaling Biotech Manufacturing Is Harder Than Scaling Innovation
The country has a strong research culture, excellent universities, and a strong ecosystem of collaboration between industry and academia.
However, scaling up manufacturing poses entirely new challenges.
The Three Phases of Biotech Growth
Most biotechnology companies go through three phases of growth:
1. Discovery and Research
Areas of focus:
Molecular biology
Pre-clinical research
Early drug discovery
The teams are small and may revolve around scientists and academia.
2. Clinical Development
Organizations begin expanding with:
- Clinical operations teams
- Regulatory affairs specialists
- Data management experts
The structure becomes more complex, but the biggest shift is still ahead.
3. Manufacturing Scale-Up
This is where biotech companies become industrial organizations.
New capabilities suddenly become essential:
- GMP manufacturing
- Quality assurance infrastructure
- Process validation
- Manufacturing operations
- Regulatory compliance programs
However, this transformation does not occur gradually.
In fact, it may take place rapidly, particularly after the release of favorable clinical trial data.
The Manufacturing Bottleneck
Throughout the Netherlands, industry leaders in the biotech industry complain about the following:
The innovation pipeline is robust.
However, challenges arise in the following ways:
- GMP manufacturing capacity
- Complexity in validation and commissioning
- Regulatory compliance
- Availability of specialized scientific staff
The outcome is that many biotech companies recognize that they must build entirely new operational structures.
The Project Structures That Enable Biotech Manufacturing Scale-Up
What are biotech companies actually doing when they scale up their manufacturing? They are not merely growing their teams. They are undertaking complex projects.
Projects may include multiple disciplines at the same time. These include engineering, regulatory affairs, quality and manufacturing operations.
The following are the most common structures that facilitate growth.
Facility Expansion Programs
When a biotech company is moving toward commercialization, the facilities become a key area.
Common expansion initiatives include:
- building GMP manufacturing facilities
- expanding cleanroom capacity
- installing stainless steel or single-use bioreactors
- establishing fill-finish production lines
Typical Facility Expansion Lifecycle
- Facility design and engineering
- Construction and installation
- Equipment qualification
- Process validation
- Regulatory readiness and inspection preparation
Each stage requires specialists with deep regulatory knowledge.
Technology Transfer Projects
Moving a process from the lab to industrial production is one of the most complex stages of biotech manufacturing.
Technology transfer typically includes:
- scaling bioprocesses from lab to production volumes
- validating analytical methods
- transferring documentation and process knowledge
- preparing regulatory submissions
Without proper coordination, this step alone can cause a manufacturing project to be delayed by months.
Commissioning, Qualification & Validation (CQV)
In a regulated environment, nothing is allowed to operate until it is validated.
CQV programs verify that equipment, facilities, and processes comply with regulatory standards.
Common roles involved are:
- Validation engineers
- QA specialists
- Regulatory affairs experts
- Process engineers
The programs are highly structured; hence, project management is a necessity.
Workforce Strategies for Scaling Biotech Manufacturing One of the most overlooked challenges facing biotech manufacturing is talent availability. In the Netherlands, the life sciences sector is blessed with a highly skilled scientist population. However, as companies grow their manufacturing operations, the nature of the profiles that are now sought are extremely specialized.
Positions Considered Always Hard to Fill Across the Netherlands, there are challenges for companies to find suitable candidates for:
The Rise of Consultant-Led Project Teams
As a solution to this problem, biotech companies use a consultant-driven project team approach.
As opposed to creating permanent teams, companies engage competent professionals to deliver a project.
For example:
- GMP implementation projects
- validation programs
- regulatory readiness initiatives
- manufacturing expansion projects
This approach allows companies to scale expertise quickly without overcommitting permanent headcount.
Hybrid Workforce Models
Successful biotech organizations typically combine:
- permanent leadership teams
- specialized consultants
- interim scientific experts
This hybrid model enables flexibility while maintaining operational continuity.
Regulatory Complexity in Biotech Manufacturing
Biotech manufacturing operates in one of the most regulated environments in the world.
Every process must comply with strict frameworks such as:
- EU GMP guidelines
- EMA regulatory standards
- data integrity requirements
- validation protocols
Even small deviations can lead to regulatory delays.
Why Regulatory Planning Must Start Early
One mistake I often see is organizations treating regulatory compliance as a final step.
In reality, compliance must be embedded from the start.
Manufacturing scale-up should involve early collaboration between:
- engineering teams
- quality assurance
- regulatory affairs
- project leadership
This alignment prevents costly delays later.
Lessons From the Dutch Biotech Ecosystem
The Netherlands has a very unique environment that is conducive to biotech development.
The combination of strong research institutions, healthcare infrastructure, and collaborative clusters has created one of Europe’s most dynamic life sciences markets.
But one pattern is increasingly clear.
Innovation alone does not scale companies.
Operational readiness does.
Organizations that successfully transition from research to manufacturing typically share several characteristics:
- strong project governance
- early regulatory alignment
- access to specialized expertise
- flexible workforce strategies
These factors allow biotechnology companies to accelerate while at the same time abiding by regulations.
The Future of Biotech Manufacturing in the Netherlands
The future, i.e., the next ten years, is promising immense growth in advanced therapies such as:
- cell therapy
- gene therapy
- biologics manufacturing
Such therapies will bring even more complexity into manufacturing operations.
The future, therefore, promises an increase in expertise in areas like:
- GMP manufacturing operations
- validation and regulatory compliance
- bioprocess engineering
- manufacturing project management
The future growth in biotechnology depends on scaling up operations.
Final Thoughts
The Netherlands certainly has all the scientific requirements in place that will propel the country to the top in the field of biotechnology.
What will propel us to the next step in our growth trajectory is not so clear, yet equally as important:
how we scale our operations.
Biotechnology manufacturing is not merely about the facilities.
It is about:
- structured project delivery
- regulatory expertise
- specialized talent
- workforce flexibility
The companies that can effectively manage scaling up operations will be able to bring new therapies into play.
FAQ’s
- Why is biotech manufacturing hard to scale?
Because it requires GMP facilities, strict regulations and specialized talent. - What project structures enable biotech scale-up?
Facility expansion, technology transfer and CQV validation programs. - Why is biotech talent scarce?
Manufacturing requires highly specialized GMP and regulatory expertise. - How do consultants help biotech companies scale?
They deliver specialized expertise for complex GMP and validation projects.
5. Why is the Netherlands important for biotech?
It offers strong research institutions, innovation hubs, and life sciences infrastructure.
Work With SIRE Life Sciences
At SIRE Life Sciences, we work closely with organizations across the Dutch life sciences ecosystem to support complex scientific and manufacturing projects.
If you are:
- An HR Director
- A Talent Acquisition leader
- A Hiring Manager
- A Procurement or Purchasing professional
- A CEO scaling operations
And if you are working on projects related to GMP manufacturing and validation, regulatory projects and scientific workforce strategies, we would be happy to start the conversation with you.
The right expertise at the right time can make a significant difference in the successful delivery of complex projects in the life sciences industry.
Let’s talk about how we can support your next chapter of growth.